Consequently, AIM2 upregulation likely reprograms the tumor immune microenvironment towards an immune-inflamed condition characterized by increased IFNγ signaling and PD-L1 expression [35] and is reported to be more responsive to ICI treatment [36]. The gene discussed is AIM2; the disease is neoplasm.